Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: Posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin

Leukemia

Volumn 22, Issue 3, 2008, Pages 496-503

  Raad, I I ^a   Hanna, H A ^a   Boktour, M ^a   Jiang, Y ^a   Torres, H A ^a   Afif, C ^a   Kontoyiannis, D P ^a   Hachem, R Y ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CASPOFUNGIN; CREATININE; ITRACONAZOLE; POSACONAZOLE; PREDNISONE; STEROID; TACROLIMUS; VORICONAZOLE;

ACUTE LEUKEMIA; ADULT; ARTICLE; ASPERGILLOSIS; CHRONIC LEUKEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER TOXICITY; LUNG ASPERGILLOSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; MYELOMA; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; SYSTEMIC MYCOSIS; TREATMENT DURATION;

EID: 40849093036     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405065     Document Type: Article

References (37)

1. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B et al. Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes. Medicine 2000; 79: 250-260.
2. Marr KA, Patterson T, Denning DW. Aspergillosis: Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16 875-894.
3. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: An update. Eur J Clin Microbiol Infect Dis 2002; 21: 161-172.
4. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-540.
5. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al., Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
6. Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P et al., European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group; Pfizer Global Aspergillus Study Group. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: Impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448-1452.
7. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: A broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5: 775-785.
8. Herbrecht R. Posaconazole: A potent, extended-spectrum triazole anti-funngal for the treatment of serious fungal infections. Int J Clin Pract 2004; 58: 612-624.
9. Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP et al. Aspergillus terreus: An emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004; 101: 1594-1600.
10. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
11. Gavalda J, Martin T, Lopez P, Gomis X, Ramirez JL, Rodriguez D et al Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis. Clin Microbiol Infect 2005; 11: 999-1004.
12. Martin MT, Gavalda J, Lopez P, Gomis X, Ramirez JL, Rodriguez D et al Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. J Antimicrob Chemother 2003; 52 1032-1034.
13. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M et al Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487-3496.
14. Ellis M, Watson R, McNabb A, Lukic ML, Nork M. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery. J Med Microbiol 2002; 51: 70-75.
15. Ryan C, McNicholsan S, O'Connell B, Forde S, Keoghan M, McCann SR. An epidemic of invasive fungal infection in a stem cell transplant unit: response to high dose liposomal amphotericin B. Hematol J 2004; 5: 548-551.
16. Caillot D, Thiebaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F et al. Liposomal amphotericin B in combination with caspofungin versus liposomal amphotericin B high dose regimen for the treatment of invasive aspergillosis in immunocompromised patients: Randomized pilot study (Combistrat Trial). Paper presented at 16th Congress of the International Society for Human and Animal Mycology (Focus on Fungal Infections 16), 8-10 March 2006; Las Vegas, NV.
17. Kontoyiannis DP, Andersson BS, Lewis RE, Raad II. Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. Clin Infect Dis 2001; 32: E94-E96.
18. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-247.
19. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA et al. Refractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025-1032.
20. Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH et al., Caspofungin Combination Therapy Study Group. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888-2897.
21. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
22. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 1996; 22 (Suppl 2): 133-144.
23. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340 764-771.
24. Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: Pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003; 188 305-319.
25. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-2956.
26. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB et al., Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients with refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
27. Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA. Salvage therapy with caspofungin for invasive aspergillosis: Results from the caspofungin compassion use study. J Infect 2005; 50: 196-205.
28. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-299.
29. Petraitiene R, Petraitis V, Groll AH, Sein T, Piscitelli S, Candelario M et al. Antifungal activity and pharmacokinetics of posaconazole (SCH56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45: 857-869.
30. Najvar LK, Cacciapuoti A, Hernandez S, Halpern J, Bocanegra R, Gurnani M et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: Comparative studies in two laboratories. Antimicrob Agents Chemother 2004; 48: 758-764.
31. Krishna G, Wexler D, Shah A, Martinho M, Patino H. The Pharmacokinetics of Oral Posaconazole in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation with Graft-versus-Host Disease. Paper presented at 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 16-19 December 2005; Washington, DC.
32. Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006; 50: 1881-1883.
33. Boucher HW, Groll AH, Chiou CC, Walsh TJ. New systemic antifungal agents: Pharmacokinetics, safety and efficacy. Drugs 2004; 64 1997-2020.
34. Spanakis EK, Aperis G, Mylonakis E. New agent for the treatment of fungal infections: Clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43: 1060-1068.
35. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host-disease. N Engl J Med 2007; 356: 335-347.
36. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C et al. Safety of long-term oral posaconazole in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42 1726-1734.
37. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E et al. AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 2007; 44: 1289-1297.